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Abstract
Background: Colorectal cancer is a significant issue internationally, with over 1.3 million people diagnosed
annually. Survival rates are increasing as treatments improve, although physical symptoms can persist despite
eradication of the tumour. In order to optimize survivorship care, further research is warranted in relation to
symptom burden. Therefore, the objectives of this study are to (i) investigate frequency of physical symptoms in
colorectal cancer survivors (ii) identify which symptoms occur together (iii) examine the associations between
demographic and clinical variables, and symptoms.
Methods: Participants nine months to three years post diagnosis were identified from the population-based
National Cancer Registry Ireland. Respondents completed the EORTC QLQ-C30 and EORTC QLQ-CR29. Reported
physical symptom frequencies were transformed into continuous scale variables, which were then analysed using
one way analysis of variance, general linear modelling and Spearman rank correlations.
Results: There were 496 participants. Fatigue, insomnia and flatulence were the most frequent symptoms, with
≥20% of respondents reporting these to be often present in the previous week. Eight other symptoms were
experienced often by 10–20% of respondents. At least one of these eleven most common symptoms was
experienced frequently by almost every respondent (99%). 66% of respondents experienced at least two of these
symptoms together, and 16% experienced five or more together. Current stoma was the single most common
variable associated with increased symptom scores, although statistically significant relationships (p ≤ 0.05) between
symptom frequency scores and clinical/demographic variables were generally weak (R-sq value ≤0.08).
Conclusion: Findings may inform targeted interventions during the nine month to three year post diagnosis
timeframe, which would enable supported self-management of symptoms.
Keywords: Survivorship, Colorectal Cancer, Symptoms
Background
Colorectal cancer is a very significant issue worldwide
with over 1.3 million people diagnosed annually [1]. How-
ever, developments in detection and treatments have led
to improving survival rates, with five year survivorship in-
creasing by 2.7% each year between 2007 and 2013 in the
United States, and in the United Kingdom, rates of sur-
vival have more than doubled in the last 40 years [2, 3].
These trends suggest the colorectal cancer survivor popu-
lation will continue to grow [4, 5]. The domino effect of
this is increased survivorship burden, as current research
indicates that physical symptoms can persist despite eradi-
cation of the tumour [6–15].
In the first year post completion of treatment, survivors
may experience multiple moderate to severe physical
symptoms [6–8]. These include diarrhoea, flatulence, fre-
quent defecation, urinary frequency, abdominal pain, nau-
sea and vomiting and fatigue [6–11]. While many of these
symptoms improve somewhat one year post treatment [9],
some can continue into longer term survivorship with
bowel issues and fatigue being identified as common per-
sistent symptoms [12–14]. In terms of symptoms and
other potentially influencing factors, evidence is limited
and somewhat contradictory. For example, in 2016, Foster
et al. [7] found that site had little effect on symptoms up
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to two years after treatment whereas both Di Fabio et al.
(2008) and Knowles et al. (2013) reported bowel symptoms
to be more problematic for rectal cancer patients [16, 17].
In relation to stoma, it has been indicated that those who
had an ostomy reversal had more bowel issues than those
who retained a stoma [18], although these findings were
not confirmed in another large scale study [13]. Age has
also been reported as influential, with younger survivors ex-
periencing a higher number of symptoms [13, 19, 20].
The results of these studies suggest that although
some consensus exists in terms of time since treatment
and the influence of age on symptoms in colorectal can-
cer survivors, existing evidence is limited and informa-
tion regarding the full extent of symptoms and
survivorship is fragmented. To inform survivorship care,
it is necessary to identify specific frequently occurring
symptoms and influencing factors. It seems the optimum
timeframe to investigate this is between one and three
years after diagnosis as the specific effect of the early
post-operative period is avoided and physical symptoms
remain relatively constant at this stage [13, 14, 21].
However, within the medium term survivorship time
period, of approximately one to three years, evidence on
symptom burden in colorectal cancer survivors is scarce,
with just two studies specifically focusing on this [13,
14]. In addition, there is little literature available examin-
ing the association of symptoms with each other - only
two previous studies considered this with both studies
investigating symptoms in long term cancer survivors,
and only one focusing specifically on colorectal cancer
[22, 23]. Addressing this gap could inform future service
development and the provision of support for medium
term colorectal cancer survivors. Consequently, the aim
of this study is to investigate the frequency of symptom
occurrence, symptoms that are experienced together,
and the relationship of symptoms to demographic and
clinical factors in colorectal cancer survivors nine
months to three years post-diagnosis.
Methods
Design and participants
The study methods have been described in detail else-
where [24]. Briefly, survivors of primary invasive colo-
rectal cancer diagnosed between October 2007 and
September 2009 were identified from the National Can-
cer Registry Ireland (NCRI) in March 2010, and
screened for study eligibility by their treating clinicians.
Those on the register were excluded if their managing
clinician did not respond or they were unaware of their
diagnosis, and if they had poor understanding of English,
cognitive impairment, were too ill to participate or had
died. Study information leaflets, letters of invitation, in-
formed consent forms and questionnaires were sent to
1273 eligible individuals. Those willing to participate
returned a completed questionnaire and informed con-
sent form by post to the NCRI.
Assessment of demographic, clinical and symptom
information
Demographic and clinical data were obtained from
Registry records and from questionnaire responses. The
assessment tools used to measure symptoms were the
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire – Core 30 (EORTC
QLQ-C30) and the European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire
– Colorectal 29 (EORTC QLQ-CR29), and these have
been published previously [25]. These widely used instru-
ments with proven validity and reliability are recommended
to be used in conjunction with each other; they contain
items that measure symptom frequency in the previous
week that are relevant to those diagnosed with cancer in
general and colorectal cancer specifically [26–28].
Responses to the symptom scales (3 subscales and 4
single items on the QLQ-C30; 3 subscales on the CR29,
which included urinary frequency, blood and mucous in
stool and stool frequency, and 11 single items which in-
cluded urinary incontinence, dysuria, abdominal pain,
buttock pain, bloating, taste, flatulence, faecal incontin-
ence, sore skin, impotence and dyspareunia) were scored
using the EORTC guidelines, which involved raw scores
being transformed to a linear scale ranging from 0 to
100, with a higher score indicating that symptoms are
experienced more frequently [28–30]. According to the
scoring procedures, patients that experienced a symp-
tom ‘quite a bit’ or ‘very much’ score ≥ 51 on the relevant
subscale, whereas those that score ≤ 50 indicated a
symptom was ‘not at all’ present, or there ‘a little’ [28,
30, 31]. In the current study, for the most part, analysis
is performed with the symptom scores, but the percent-
age of participants who scored ≥51 is also examined, in
order to indicate the most frequently reported
symptoms. In this study, respondents with a symptom
score ≥ 51 are described as experiencing a symptom
“frequently” or “often” and the symptoms with the high-
est mean scores are described as the “common” or
“commonly-reported” symptoms. When a respondent’s
score is ≥51 on two symptoms, it is indicated that these
two symptoms “occur together”.
Statistical methods
The statistical package SPSS v.22 was used for analysis.
Means and standard deviations of the symptom score
scale data were used to identify the commonly-reported
symptoms. Spearman rank correlations between scores
for pairs of symptoms were used to identify symptoms
which tended to occur together; a priori, a rank correl-
ation of 0.30, as the lower bound was applied for this
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purpose. Bivariate analyses of the relationships between
symptom scores and clinical/demographic variables were
based on one-way analysis of variance (ANOVA) and
statistically significant results are reported. As an add-
itional measure, corresponding non-parametric analyses
using Kruskal-Wallis tests were also carried out, and any
additional significant results noted and reported. The
choice of ANOVA was made because it gives more read-
able output (mean scores) than the non-parametric ap-
proach (which uses ranks). The main purpose here was
to identify which symptoms were associated with which
factors; the non-parametric tests were included in order
to identify any that were missed by the parametric ap-
proach. General linear models were fitted separately for
each symptom score, to test for relationships of demo-
graphic and clinical variables to symptom scores. Selec-
tion of explanatory variables for these general linear
models followed a standard search procedure: choice of
the initial multi-variable models was based on earlier bi-
variate results, and statistically non-significant explana-
tory variables were then removed, one by one, from each
multi-variable model, until only significant variables
remained. Participants with missing values were omitted
from any analyses involving those variables. The 5% level
of significance was used in analysis of variance and gen-
eral linear models, without correction for multiple tests.
Results
Response rate and sample size
The total number of participants in the study sample
was 496, yielding a response rate of 39%. The proportion
of non-responders was significantly higher in the age
group ≥75 years, but there were no statistically signifi-
cant differences between responders and non-responders
for gender, tumor site, treatment received, stage at diag-
nosis or time since diagnosis.
Demographic and clinical characteristics of responders
The demographic and clinical characteristics of the
study participants are summarised in Table 1. The age
range of participants was 26–93 years, with mean age
(±sd) = 67.4(±11.6). Almost two-thirds were male (63%)
and 62% had colon cancer. Slightly more than one in five
participants (22%) reported having a stoma at the time
of survey completion. Most survivors (86%) had under-
gone surgical resection of the colon or rectum, with or
without chemotherapy or radiotherapy.
Symptom frequency scores
Means and standard deviations of the symptom scores
are presented in Table 2, and also the percentages of
participants experiencing each symptom frequently in
the previous week (i.e. responding “quite a bit” or “very
much”). The three most common symptoms (each
scored as ≥51 by more than 20% of respondents) were
fatigue, insomnia and flatulence. Scored as ≥51 by 10–
20% of respondents were eight additional symptoms:
constipation, diarrhea, bloating, appetite loss, weight
Table 1 Demographic and clinical characteristics
All respondents (n = 496)a
n %
Gender
Female 186 37.5
Male 310 62.5
Age at survey
≤ 54 years 69 13.9
55–64 years 130 26.2
65–74 years 177 35.7
≥ 75 years 120 24.2
Marital status
Single 36 7.4
Married 369 75.6
Separated / widowed 83 17.0
Highest education level
Primary school 149 30.5
Secondary school 230 47.1
Third level 109 22.4
Site
Colon 307 61.9
Rectum 189 38.1
Stage at diagnosis
Stage I 90 18.1
Stage II 141 28.4
Stage III 175 35.3
Stage IV 36 7.3
Unknown/unstaged 54 10.9
Time since diagnosis
≤ 1 year 186 37.5
1–2 years 236 47.6
2–3 years 74 14.9
Stoma
Never had stoma 243 51.2
Previous stoma 127 26.7
Current stoma 105 22.1
Treatmentb
Surgical resection 427 86.3
Chemotherapy 139 28.1
Radiotherapy 81 16.4
aSome percentages calculated using denominator less than stated total due to
missing data
bTreatment within 1 year of diagnosis
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worry, dry mouth, sore skin and frequent urination. All
other symptoms were scored as ≥51 by less than 10% of
study respondents.
At least one of the eleven most common symptoms
was experienced frequently by almost every respondent
(98.8%). Nearly two-thirds of respondents (66.3%) expe-
rienced at least two of these eleven symptoms together.
More than one in seven (15.5%) experienced five or
more of these eleven symptoms together.
Relationships among symptoms
Symptoms for which the rank correlations were 0.3 or
more with other symptoms are displayed in Table 3. A
high positive correlation between two symptom scores
indicate that these symptoms tend to occur (or not) to-
gether - both are experienced, or neither are experienced
to any great extent.
The large number of significant correlations in Table 3
indicates that the range of symptoms which occur to-
gether is wide. For example, it shows that fatigue tends
to occur together with six of the other ten most com-
mon symptoms, and also with another eight of the less
commonly-reported symptoms. The highest correlation
(0.612) is between fatigue and general pain, the latter be-
ing one of the less commonly-reported symptoms; only
47 respondents (9.5%) reported experiencing general
pain frequently, but 36 of these 47 (76.6%) also reported
frequent fatigue. Similarly, while nausea/vomiting was
common in only 21 respondents, 19 of these 21(90.5%)
also reported frequent fatigue.
Relationships between symptom scores, and
demographic and clinical variables
Table 4 displays the symptom scores which differ signifi-
cantly by the demographic (gender and age) and clinical
(site, stage and stoma) variables. The p-values displayed,
except where indicated otherwise, are from analysis of
variance.
Symptom scores did not differ significantly across the
six possible treatment categories (Surgery Only; Chemo-
therapy Only; Radiotherapy Only; Surgery Chemother-
apy & Radiotherapy; Surgery & Chemotherapy; Surgery
& Radiotherapy) but this finding is tentative because of
the very small numbers in some treatment categories.
When treatment was considered as binomial variables
(cancer-directed surgery yes/no, chemotherapy yes/no
and radiotherapy yes/no) just a small number of signifi-
cant relationships were identified; these included flatu-
lence (higher in those with a stoma who had
chemotherapy, p = 0.03), and abdominal pain (higher in
those that received radiotherapy, p = 0.02).
The findings from the multivariable linear models for
the eight symptoms that demonstrated statistical signifi-
cance based on bivariate results are summarized in
Table 5. More detailed information (model coefficients,
confidence intervals for these coefficients, and r-squared
values for each model), is displayed in Additional file 1:
Table S1. The r-squared values are low for all eight
models, ranging from 0.02, for the model relating
Table 2 Symptom frequency scores and percentage of subjects
experiencing each symptom often
Symptom Mean
(±SD)
Scored > 51
(‘quite a bit’/ ‘very much)
Fatigue (n = 475) 33 (±26) 120 (24.2%)
Insomnia (n = 470) 28 (±30) 109 (22.0%)
Bowel Function
- Constipation (n = 468) 17 (±27) 57 (11.5%)
- Diarrhoea (n = 467) 21 (±30) 67 (13.5%)
- Flatulence
(current stoma) (n = 107) 38 (±29) 27 (25.5%)
(no stoma) (n = 252) 37 (±32) 80 (21.6%)
(combined) (n = 359) 37 (±30) 107 (22.5%)
- Bloating (n = 471) 20 (±31) 56 (11.3%)
- Blood in stool (n = 471) 3 (±27) 5 (1.0%)
- Faecal incontinence
(current stoma) (n = 102) 27 (±11) 19 (18.1%)
(no stoma) (n = 253) 14 (±24) 22 (5.9%)
(combined) (n = 355) 18 (±27) 41 (8.6%)
- Stool frequency
(current stoma) (n = 106) 17 (±24) 8 (7.5%)
(no stoma) (n = 254) 24 (±25) 25 (6.8%)
(combined) (n = 360) 22 (±25) 33 (6.9%)
Nutrition
- Appetite loss (n = 474) 15 (±26) 56 (11.3%)
- Weight worry (n = 467) 22 (±27) 66 (13.3%)
- Taste (n = 467) 13 (±24) 38 (7.7%)
- Nausea & vomiting (n = 475) 10 (±20) 21 (4.2%)
- Dry mouth (n = 471) 17 (±27) 59 (11.9%)
Pain
- General pain (n = 474) 19 (±25) 47 (9.5%)
- Abdominal pain (n = 469) 12 (±22) 32 (6.5%)
- Buttock pain (n = 466) 14 (±25) 45 (9.1%)
Dermatological Issues
- Sore skin
(current stoma) (n = 105) 27 (±30) 20 (19.0%)
(no stoma) (n = 253) 18 (±27) 31 (8.4%)
(combined) (n = 358) 21 (±28) 51 (10.7%)
Urinary Issues
- Dysuria (n = 470) 4 (±15) 11 (2.2%)
- Urinary frequency (n = 466) 33 (±26) 82 (16.5%)
- Urinary incontinence (n = 465) 12 (±22) 27 (5.4%)
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urinary frequency to age, up to 0.08, for the relationship
of buttock pain to age, site and stoma. Variation in these
demographic and clinical variables, therefore, explains
only a small proportion of variation in these symptom
scores. Stoma is significantly related to five of the eight
symptoms. Site is related to four symptoms, age is asso-
ciated with three symptoms and gender is related to two
symptoms.
Discussion
In this study, symptom frequency, symptoms that occur
together, and the clinical and demographic variables as-
sociated with such symptoms were investigated in colo-
rectal cancer survivors nine months to three years post
diagnosis. The results indicate that three symptoms - fa-
tigue, insomnia and flatulence - remain frequent for
some individuals nine months to three years following
diagnosis. Moreover, it has been demonstrated that in
colorectal cancer survivors nine months to three years
post diagnosis, symptoms tend to occur together rather
than in isolation. Additionally, in relation to clinical vari-
ables, those with a stoma reported higher scores for sev-
eral symptoms. Consequently, it is evident that symptom
burden exists for groups of individuals, which is often
multidimensional in nature.
Regarding symptom presentation, fatigue, insomnia
and flatulence, were scored as ≥51 on a scale of 0–100
in more than 20% of the study participants. The findings
in relation to fatigue and insomnia are also reflected in
previous studies that investigated these symptoms in
colorectal cancer survivors [12, 13, 15]. Results of a
cross-sectional study that examined symptoms and qual-
ity of life in colorectal cancer survivors within a similar
timeframe of post diagnosis indicated that 40% of the
sample had trouble sleeping and felt tired [13]. That
study had a larger sample size and higher response rate
than the current study and the two studies used different
instruments to assess sleep problems. Furthermore, in
that study 20% of survivors reported having little or no
appetite [13] which supports the findings of the current
investigation where 10% to 20% of respondents scored
≥51 for the symptoms of appetite loss, weight worry and
dry mouth. The two studies reported similar prevalence
of frequent urination (17% here vs 13% by Downing et
al. (2015)) [13]. Interestingly, when compared with the
general population, research in the United States has in-
dicated that older survivors of colorectal cancer reported
similar levels of urinary issues [32], thus demonstrating
that other variables may be influential.
Therefore, in order to gain a more comprehensive
view, it is necessary to consider the effect of other vari-
ables on symptom scores, thus warranting further exam-
ination of the association of symptoms with one
another. As well as being the most common symptoms,
fatigue, insomnia and flatulence, tended to occur to-
gether, and with many other symptoms. Of particular
note were the associations between fatigue, insomnia,
bloating, nausea and vomiting and general pain. In
addition, fatigue also correlated with diarrhea, weight
worry, taste, dry mouth, abdominal and buttock pain,
flatulence and stool frequency. Consequently, the results
of this current investigation strongly indicate that symp-
toms do not occur in isolation. A recent study that ex-
amined symptom clusters in colorectal cancer survivors
≤ 2 years and ≥ 10 years post diagnosis confirms this,
with anxiety, fatigue and depression clustering, in
addition to pain and insomnia [23]. However, in that
study only five other symptoms in addition to fatigue
were analyzed [23]. Therefore, the current investigation
offers a more comprehensive view and demonstrates
that although symptom scores may be higher for certain
symptoms, in order to optimize survivorship care, these
cannot be considered as singular issues.
In relation to the influence of clinical and demo-
graphic variables on symptoms, results of the current
study should be interpreted with caution as, although
there were a range of statistically significant relationships
between clinical and demographic variables and symp-
toms, following multivariate analysis, these relationships
were generally weak, with more than 90% of variance of
symptom scores remaining unexplained by such vari-
ables. In terms of understanding this variance in symp-
tom scores further, this may be explained by examining
other variables that were not analyzed here, such as
Table 5 Summary of results from multivariable models:
statistically significant relationships between higher symptom
scores and multiple demographic/clinical variablesa
Symptom Bivariate Relationships Multivariate Relationships
Abdominal pain ≤54 years
Current stoma
Female gender
Rectal cancer
≤54 years
Rectal cancer
Insomnia Female gender
Current stoma
Female gender
Current stoma
Diarrhoea Rectal cancer
Previous stoma
Rectal cancer
Appetite loss Female gender
Current stoma
Female gender
Current stoma
Buttock pain ≤54 years
Rectal cancer
Previous stoma
≤54 years
Rectal cancer
Previous stoma
Sore skin 55–64 years
Current stoma
Current stoma
Urinary frequency Male gender
≥65 years
≥65 years
Urinary incontinence Rectal cancer
Current stoma
Rectal cancer
Current stoma
aThere were no other significant bivariate or multivariate relationships for all
other symptoms
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co-morbidities and psychological distress, both of which
have been previously identified as influential [23]. There-
fore, when findings of the current investigation are ex-
amined in isolation, this suggests that the clinical and
socio-demographic data are of limited use in helping tar-
get supportive care interventions. However, the results
from the analysis of these variables in this study are sup-
ported by findings of previous investigations.
Regarding presence of a stoma, this was identified as
the single most common factor associated with in-
creased symptom scores. Interestingly, Downing et al.
(2015) indicated that the presence of a stoma signifi-
cantly reduced the proportion of respondents reporting
‘perfect’ health when compared with those that had no
stoma (19% versus 40%) [13]. Existing literature in rela-
tion to the influence of site on symptoms also supports
the findings of the current study, in that survivors of
rectal cancer report higher symptom scores than those
diagnosed with colon cancer [13, 16, 17]. In addition,
consensus also exists in terms of age and the presence of
symptoms associated with colorectal cancer survivor-
ship, with more problems reported by younger respon-
dents [13, 14]. It has been suggested that the influence
of age on the burden of disease may explain these find-
ings, as older adults may assess their physical health in
terms of their peers, rather than the ideal of perfect
health [14]. There was also little or no statistical evi-
dence of a relationship between symptom scores and
stage of cancer, type of cancer treatment, or time since
diagnosis. Regarding treatment, results of the current in-
vestigation agree with previous studies of longer term
survivors [9, 18]. Existing literature that examined the
influence of time since diagnosis on symptoms is limited
to just a single study within the one to three year time
frame; this reports similar findings to the current inves-
tigation, with only modest improvements noted from the
first to the third year after diagnosis. The study which
has been discussed previously, that also identified symp-
tom clusters in colorectal cancer survivors, albeit over a
longer time frame post diagnosis (≤ 2 years and ≥ 10 years)
similarly reported that time since diagnosis demonstrated
little influence on symptom burden [23].
There are a number of limitations in relation to the
current investigation that require consideration. Specifically
in relation to surgical resection of the colon or rectum, re-
sults of this study are slightly higher than rates reported by
Carsin et al. (2008) [33] on colorectal cancer treatment pat-
terns in Ireland for this time (86% versus 78%). However, it
must be noted that endoscopic surgery for removal of early
stage tumors was not recorded and so there may be incom-
plete surgery data for the remaining 14% of the sample in-
vestigated which must be considered, as the type of surgery
should not be neglected as a potential influencing factor on
symptom presentation. In addition, it is not possible to
disentangle colorectal cancer specific symptoms and gen-
eral symptoms due to the lack of a non-cancer control
group as well as information regarding comorbidities. Also,
the low overall response rate of 39% and a significant pro-
portion of non-responders in the age category ≥75 years
may have led to an imprecise estimation of symptom scores
in this study. The actual number of symptoms experienced
frequently, and experienced together, may be even higher
than reported here. Clinically, symptoms present nine
months to three years post diagnosis should not, therefore,
be considered in isolation. This may inform future colorec-
tal cancer survivorship care.
The major recommendation for practice that follows
from these findings is that there should be thorough as-
sessment of the presence of symptoms in the follow-up
of medium term colorectal cancer survivors, in order to
inform tailored patient-centred support and care. There
needs to be heightened awareness among the clinical
team, that symptoms tend to be multi-dimensional in
nature in this patient group and that those patients with
a stoma may be more likely to need support. In addition,
particular attention should be paid to assessing and pro-
viding support around fatigue, insomnia and flatulence.
Conclusion
This study identified that fatigue, insomnia and flatulence
were the most common symptoms in colorectal cancer sur-
vivors nine months to three years post their diagnosis, and
that these symptoms, and many others, tended to occur to-
gether. In addition, presence of a current stoma was the
single most common factor associated with increased
symptom scores, although this relationship was weak, des-
pite reaching statistical significance. These findings may in-
form clinical practice as the identification, implementation
and evaluation of targeted interventions during the nine
month to three year post diagnosis timeframe would enable
supported self-management of problematic symptoms such
as fatigue, insomnia and flatulence, particularly in relation
to those with a stoma. In addition, research exploring the
influence of symptoms on quality of life and functioning is
required in order to gain a more comprehensive view of
the consequences of symptom burden.
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